Oxazolidinones in the Clinical Management of Staphylococcal Infection—Linezolid or Tedizolid? A review on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS)
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag323 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Liana Macpherson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infection, Guy's and St Thomas' NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Staphylococcal Infections, Oxazolidinones, Linezolid. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Health and Care Research, Medical Research Council.
Abstract (Originalsprache)
There is limited information in the existing literature regarding the choice of oxazolidinone in clinical practice to treat infections caused by staphylococcal species. As members of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS) we have collaborated and written this narrative review aimed at clinicians considering these agents in practice. The review focuses on two medications, linezolid and tedizolid, with a comprehensive description of pharmacology aspects, adverse effects, drug interactions and contraindications, and we investigate the potential for treatment optimization. We anticipate that this article will provide support for those considering utilization of linezolid and tedizolid in clinical practice to treat staphylococcal species.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infection, Guy's and St Thomas' NHS Foundation Trust, London, UK.
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS).
- Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.
- Department of Infectious Diseases and Clinical Microbiology, Clínica Universidad de Navarra, Pamplona, Spain.
- IdiSNA, Navarra Institute for Health Research, Navarra, Spain.
- Innovative Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
ORCID-Profile: Liana Macpherson, Anna L Goodman
Förderung
- National Institute of Health and Care Research
- Medical Research Council
Zitieren
APA
Macpherson, L., Martson, A. G., Del Pozo, J. L., Zheng, C., & Goodman, A. L. (2026). Oxazolidinones in the Clinical Management of Staphylococcal Infection—Linezolid or Tedizolid? A review on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS). Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag323
Vancouver
Macpherson L, Martson AG, Del Pozo JL, Zheng C, Goodman AL. Oxazolidinones in the Clinical Management of Staphylococcal Infection—Linezolid or Tedizolid? A review on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS). Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag323
BibTeX
@article{Macpherson2026,
author = {Macpherson, Liana and Martson, Anne-Grete and Del Pozo, Jose L and Zheng, Cindy and Goodman, Anna L},
title = {Oxazolidinones in the Clinical Management of Staphylococcal Infection—Linezolid or Tedizolid? A review on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS)},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag323}
}
EUVIMED